We published this short notification below in our News section on August 15, 2022, but have decided to retire the News section and post news as Blog instead. This is a link to the article on PubMed, National Library of Medicine.
A new review titled “Pharmacological Therapies for Connective Tissue Fibrosis in Orthopaedics” by N. Disser et.al has been published in The American Journal of Sports Medicine.
They summarise by stating “Based on our review, it would appear that over-the counter food supplements and ‘‘nutraceuticals’’ hold promise as agents to prevent connective tissue fibrosis with a good safety profile. In particular, EGCG and quercetin appear to be safe and reasonable candidates for further study. FDA-approved medications that may be considered for off-label use for prevention of connective tissue fibrosis include losartan, anakinra, and sotatercept.”